UniSuper Management Pty Ltd Purchases Shares of 6,113 Cencora, Inc. (NYSE:COR)

UniSuper Management Pty Ltd purchased a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,113 shares of the company’s stock, valued at approximately $1,485,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Seven Eight Capital LP bought a new stake in shares of Cencora in the 1st quarter valued at about $7,191,000. Invesco LLC bought a new stake in shares of Cencora in the 1st quarter valued at about $428,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Cencora in the 1st quarter valued at about $9,770,000. Ameritas Investment Partners Inc. acquired a new position in shares of Cencora in the 1st quarter valued at about $465,000. Finally, Alerus Financial NA acquired a new position in shares of Cencora in the 1st quarter valued at about $9,761,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. SVB Leerink reissued an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Citigroup boosted their price objective on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Robert W. Baird boosted their price objective on Cencora from $280.00 to $285.00 and gave the company an “outperform” rating in a research note on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $238.78.

Cencora Stock Down 0.2 %

COR stock traded down $0.46 during trading on Tuesday, reaching $224.26. 678,255 shares of the stock were exchanged, compared to its average volume of 1,369,467. The firm’s 50 day moving average is $226.62 and its 200 day moving average is $230.33. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The firm has a market cap of $44.73 billion, a P/E ratio of 24.60, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. During the same period in the prior year, the business earned $3.50 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 13.46 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Transactions at Cencora

In related news, Director Dermot Mark Durcan acquired 500 shares of the stock in a transaction dated Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the purchase, the director now directly owns 21,876 shares in the company, valued at approximately $4,781,656.08. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now directly owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Dermot Mark Durcan bought 500 shares of Cencora stock in a transaction dated Friday, May 24th. The stock was acquired at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the acquisition, the director now owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The disclosure for this purchase can be found here. Insiders sold a total of 1,899,112 shares of company stock valued at $408,654,376 over the last ninety days. 15.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.